Early on during MAPK inhibitor treatment, melanomas undergo dedifferentiation/quasi-mesenchymal transition and upregulate tumor cell surface PD-L1/L2 [76 Cancer stemness or quasi-mesenchymal phenotype is associated with abundant PD-L1, immunosuppression, metastases, and therapy resistance in general. This evidence concerns the gene CD274 and neoplasm.